



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/030,571	02/24/1998	CHARLES R. CANTOR	25491-2401G	7542
20985 75	90 02/16/2006		EXAMINER	
FISH & RICHARDSON, PC			FORMAN, BETTY J	
P.O. BOX 1022 MINNEAPOLI	S, MN 55440-1022		ART UNIT	PAPER NUMBER
	•, ••••		1634	
			DATE MAILED: 02/16/2006	6

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
Office Action Summary		09/030,571	CANTOR ET AL.					
		Examiner	Art Unit					
		BJ Forman	1634					
Period fo	The MAILING DATE of this communication or Reply	n appears on the cover she	et with the correspondence ac	ddress				
WHIC - Exter after - If NO - Failur Any r	ORTENED STATUTORY PERIOD FOR REHEVER IS LONGER, FROM THE MAILIN asions of time may be available under the provisions of 37 C SIX (6) MONTHS from the mailing date of this communication period for reply is specified above, the maximum statutory pre to reply within the set or extended period for reply will, by reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMM FR 1.136(a). In no event, however, r on. eriod will apply and will expire SIX (6 statute, cause the application to become	IUNICATION. nay a reply be timely filed i) MONTHS from the mailing date of this come ABANDONED (35 U.S.C. § 133).					
Status								
1)	Responsive to communication(s) filed on	16 November 2005						
		This action is non-final.						
′=	/ 		matters, prosecution as to the	e merits is				
-,	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠	Claim(s) 74-76.92-94.123.124.127-133 ar	nd 135-139 is/are pending	in the application.					
	4)⊠ Claim(s) 74-76,92-94,123,124,127-133 and 135-139 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) 74-76,92-94,123,124 and 136 is/are allowed.							
·	6)⊠ Claim(s) <u>127-133,135 and 137-139</u> is/are rejected.							
	Claim(s) is/are objected to.	•						
	Claim(s) are subject to restriction a	nd/or election requiremen	t.					
Applicati	on Papers							
9)[7]	The specification is objected to by the Exa	miner						
	The drawing(s) filed on is/are: a)□		d to by the Examiner					
	Applicant may not request that any objection to		•					
	Replacement drawing sheet(s) including the co	- .,	•	FR 1 121(d)				
	The oath or declaration is objected to by the	•	• • •	` '				
	nder 35 U.S.C. § 119							
	Acknowledgment is made of a claim for for	eign priority under 35 H S	.C. 8 119(a)-(d) or (f)					
_	☐ All b)☐ Some * c)☐ None of:	eigh phonty under 55 0.0	.o. g 115(a)-(a) or (i).					
,-	1. Certified copies of the priority docur	nents have been received						
	Certified copies of the priority docur							
	Copies of the certified copies of the			Stane				
	application from the International Bu			- Clago				
* S	ee the attached detailed Office action for a	•						
Attachment	(s)							
	e of References Cited (PTO-892)	4) 🔲 Interv	view Summary (PTO-413)					
	e of Draftsperson's Patent Drawing Review (PTO-948	B) Pape	r No(s)/Mail Date	0.450)				
	nation Disclosure Statement(s) (PTO-1449 or PTO/S No(s)/Mail Date	B/08) 5)	e of Informal Patent Application (PTC r:	O-152)				

Application/Control Number: 09/030,571 Page 2

Art Unit: 1634

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 16 November 2005 has been entered.

Status of the Claims

2. This action is in response to papers filed 16 November 2005 in which claims 74, 127 and 135 were amended and claims 70, 72-73 and 77-79 were canceled. All of the amendments have been thoroughly reviewed and entered.

The previous rejections in the Office Action dated 14 July 2005, not reiterated below are withdrawn in view of the amendments. Applicant's arguments have been thoroughly reviewed but are deemed moot in view of the amendments and new grounds for rejection. New grounds for rejection are discussed.

Claims 74-76, 92-94, 123-124, 127-133 and 135-139 are under prosecution.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 127-133, 135, 137-139 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Independent Claim 127 (from which the remaining claims depend) has been amended to define the selected base as being one of "adenosine-5'-phosphate. deoxyadenosine-5'-phosphate, deoxythymidine-5'-phosphate, uridine-5'-phosphate, guanine-5'-ohosphate, deoxyguanosine-5'-phosphate, cytidine-5'-phosphate or deoxycytidine-5'-pohosphate".

Applicant points to pages 10 and 12 to support the added limitation. Page 10 defines the bases present in DNA and RNA. Page 12 defines the probe subsets as follows:

The probes are divided into four subsets. In each, one of the four bases is used at a defined number of positions and all other bases except that one on the remaining positions. Probes from the first subset contain two elements, A and non-A (A = adenosine).

The passage does not define or limit "non-A". The passage does not define or limit the four bases to those previously described (e.g. those cited on page 10). Applicant appears to be amending the claims to overcome the probe sets comprising ddNTP in the cited reference. The instant specification provides no teaching of the newly claimed probe sets. In contrast to a supportive teaching, the specification (on page 13), which immediately follows the cited passage, specifically teaches use of ddNTP. Therefore, the specification does not provide any disclosure to support the newly claimed probe sets.

MPEP 2163.06 notes "If New Matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112, first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981)." MPEP 2163.02 teaches that "Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed...If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application." MPEP 2163.06 further notes "When an amendment is filed in REPLY TO AN OBJECTION OR REJECTION BASED ON 35 U.S.C. 112, FIRST PARAGRAPH, A STUDY OF THE ENTIRE APPLICATION IS OFTEN NECESSARY TO DETERMINE WHETHER OR NOT "NEW MATTER" IS INVOLVED.

Art Unit: 1634

APPLICANT SHOULD THEREFORE SPECIFICALLY POINT OUT THE SUPPORT FOR ANY AMENDMENTS MADE TO THE

DISCLOSURE" (emphasis added).

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 6. Claims 127-133, 135, 137-139 are rejected under 35 U.S.C. 102(b) as being anticipated by Holmes et al (W0 90/06045, published 14 June 1990).

Regarding Claim 127, Holmes et al discloses an array of probes wherein each probe comprises a single-stranded portion comprising a variable region (non-hybridized target) and a double-stranded portion (oligo-dT) wherein the probes are divide into four subsets wherein each subset a nucleic acid base occupies a defined number of positions (e.g. biotinylated nucleotide at the end, page 8, lines 7-11 or incorporated ddNTP, page 14, lines 1-15) and all other bases (non-biotinylated A, T, C, G) occupy the remaining positions (page 15, lines 15-35).

The above interpretation of Holmes describes the double stranded portion of the probes following primer extension and NTP incorporation to complement a portion of the single stranded portion.

Prior to primer extension, the single stranded portion of the probes has the complement i.e. the single stranded portion of each set has a base at a defined number of positions and all other bases occupy the remaining positions as evidenced by the extension product and the selected base is one of those claimed. Therefore, the hybridized and unextended probes of Holmes are encompassed by the claims as amended.

Application/Control Number: 09/030,571

Art Unit: 1634

Regarding Claims 138 and 128, Holmes et al disclose the array wherein the probes are fixed to a solid support via a coupling agent e.g. biotin (page 8, lines 7- 11 and page 11, lines 23-26).

Regarding Claim 129, Holmes et al disclose the array wherein the probes are labeled (page 15, lines 15-35).

Regarding Claim 130, Holmes et al disclose the array wherein the label is a radioisotope or florescent molecule (page 13, line22-page 14, line 29).

Regarding Claim 131, Holmes et al disclose the array wherein the nucleic acids are DNA or RNA (page 2, lines 9-22).

Regarding Claim 132, Holmes et al disclose the array wherein the solids support is metal (page 4, lines 14-35).

Regarding Claim 133, Holmes et al disclose the array wherein the solid support is threedimensional having multiple binding sites (page 5, line 19-page 7, line 9).

Regarding Claim 135, Holmes et al disclose the array wherein the probes comprise a base analog (i.e. biotintylated nucleotide at the end, page 8, lines 7- 11).

Regarding Claim 136, Holmes et al disclose the array wherein the double stranded portion includes a restriction site (page 18, lines 32-37).

Regarding Claims 137, Holmes et al disclose the array wherein the probes are fixed to a solid support via a coupling agent e.g. biotin (page 8, lines 7-11 and page 11, lines 23-26).

Regarding Claims 138, Holmes et al disclose the array wherein the probes are fixed to a solid support via a coupling agent e.g. biotin (page 8, lines 7- 11 and page 11, lines 23-26).

Regarding Claims 139, Holmes et al disclose the array wherein the probes are fixed to a solid support (page 8, lines 7- 11 and page 11, lines 23-26).

Response to Argument

7. Applicant argues that Holmes teaches the probes wherein the selected base is the incorporated ddNTP. Applicant asserts that the claims, as amended, define the selected base

Art Unit: 1634

over the ddNTP of Holmes. The argument has been considered but is not found persuasive because, as stated above, the probes, prior to ddNTP incorporation contain a single stranded portion having the complement to the subsequently extended portion. This complement does not contain the ddNTP, but the complement to the ddNTP. Therefore, the hybridized probes of Holmes are encompassed by the claimed probes. It is noted that the claims do not define the selected nucleotide base as being part of the single stranded or double stranded portion. For this additional reason, the probes of Holmes are encompassed by the claimed probes.

Conclusion

- 8. Claims 74-76, 92-94, 123-124 and 135 are free of the prior art and may be placed in condition for allowance following resolution of the above rejections.
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (571) 272-0741. The examiner can normally be reached on 6:00 TO 3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (571) 272-0745. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Application/Control Number: 09/030,571

Art Unit: 1634

BJ Forman Ph.D. Primary Examiner Art Unit: 1634 February 13, 2006